放疗与免疫治疗在恶性肿瘤治疗中的相互作用
The Interaction between Radiotherapy and Immunotherapy in the Treatment of Ma-lignant Tumors
摘要: 大部分被诊断为恶性肿瘤的患者将在病程中接受放疗,在以治疗或缓解病痛为目的的传统上,以往放射治疗的有效性仅被解释为治疗体积内针对肿瘤细胞DNA的不可修复性损伤,导致细胞死亡或丧失复制潜能。在过去的几年里,免疫检查点抑制剂的出现,改变了很多恶性肿瘤的治疗现状,为抗肿瘤治疗提供了新的努力方向和希望。然而,越来越多的数据表明,免疫系统也是放疗反应的关键性决定因素,放射和免疫联合治疗可能是协同作用。这种联合可能提供一种非药理学、低毒性和较经济的方法来增加全身反应和最大限度地增加肿瘤细胞的死亡。该综述主要基于免疫时代的到来改变了恶性肿瘤治疗模式、放疗与免疫治疗联合的理论机制,及在联合治疗过程中需要关注的问题展开,并提出了对联合方案的优化,并对未来将面临的挑战和发展方向提出总结与展望。
Abstract: Most patients diagnosed with malignant tumors will receive radiation therapy during the course of the disease. Traditionally, the effectiveness of radiation therapy was only explained as irreparable damage to tumor cell DNA within the treatment volume, leading to cell death or loss of replication potential, with the aim of treating or alleviating pain. In the past few years, the emergence of im-mune checkpoint inhibitors has changed the current treatment status of many malignant tumors, providing new directions and hope for anti-tumor treatment. However, an increasing amount of da-ta suggests that the immune system is also a key determinant of radiation response, and the com-bination of radiation and immune therapy may be a synergistic effect. This combination may pro-vide a non pharmacological, low toxicity, and more economical method to increase systemic reac-tions and maximize tumor cell death. This review is mainly based on the arrival of the immune era, which has changed the treatment mode of malignant tumors, the theoretical mechanism of the combination of radiotherapy and immunotherapy, and the issues that need to be paid attention to during the combined treatment process. It also proposes the optimization of the combined plan, and summarizes and prospects the challenges and development directions that will be faced in the future.
文章引用:陈悦, 赵红. 放疗与免疫治疗在恶性肿瘤治疗中的相互作用[J]. 临床医学进展, 2023, 13(7): 11272-11279. https://doi.org/10.12677/ACM.2023.1371575

参考文献

[1] Barbari, C., et al. (2020) Immunotherapies and Combination Strategies for Immuno-Oncology. International Journal of Molecular Sciences, 21, Article 5009. [Google Scholar] [CrossRef] [PubMed]
[2] Herrera, F.G., et al. (2019) Ra-tional Combinations of Immunotherapy with Radiotherapy in Ovarian Cancer. The Lancet Oncology, 20, e417-e433. [Google Scholar] [CrossRef
[3] Takahashi, J. and Nagasawa, S. (2020) Immunostimulatory Effects of Radiotherapy for Local and Systemic Control of Melanoma: A Review. International Journal of Molecular Sciences, 21, Article 9324. [Google Scholar] [CrossRef] [PubMed]
[4] Zietman, A.L. and Yom, S.S. (2020) Radiation Therapy and the Im-mune System: A Scientific Revolution in the Making. International Journal of Radiation Oncology, Biology, Physics, 108, 1-2. [Google Scholar] [CrossRef] [PubMed]
[5] Turgeon, G.A., Andrew, W., Arun, A.A., Benjamin, S. and Shankar, S. (2019) Radiotherapy and Immunotherapy: A Synergistic Effect in Cancer Care. Medical Journal of Australia, 210, 47-53. [Google Scholar] [CrossRef] [PubMed]
[6] Brandmaier, A. and Formenti, S.C. (2020) The Impact of Ra-diation Therapy on Innate and Adaptive Tumor Immunity. Seminars in Radiation Oncology, 30, 139-144. [Google Scholar] [CrossRef] [PubMed]
[7] Deng, L., et al. (2014) Irradiation and Anti-PD-L1 Treatment Synergistically Promote Antitumor Immunity in Mice. The Journal of Clinical Investigation, 124, 687-695. [Google Scholar] [CrossRef
[8] Janopaul-Naylor, J.R., Shen, Y., Qian, D.C. and Buchwald, Z.S. (2021) The Abscopal Effect: A Review of Pre-Clinical and Clinical Advances. International Journal of Molecular Sciences, 22, Arti-cle 11061. [Google Scholar] [CrossRef] [PubMed]
[9] Demaria, S. and Formenti, S.C. (2020) The Abscopal Effect 67 Years Later: From a Side Story to Center Stage. The British Journal of Radiology, 93, 20200042. [Google Scholar] [CrossRef] [PubMed]
[10] Abuodeh, Y., Venkat, P. and Kim, S. (2016) Systematic Review of Case Reports on the Abscopal Effect. Current Problems in Cancer, 40, 25-37. [Google Scholar] [CrossRef] [PubMed]
[11] Monjazeb, A.M., et al. (2020) Effects of Radiation on the Tumor Microenvironment. Seminars in Radiation Oncology, 30, 145-157. [Google Scholar] [CrossRef] [PubMed]
[12] Zhang, Z., Liu, X., Chen, D. and Yu, J. (2022) Radiotherapy Combined with Immunotherapy: The Dawn of Cancer Treatment. Signal Transduction and Targeted Therapy, 7, Article No. 258. [Google Scholar] [CrossRef] [PubMed]
[13] Rodríguez-Ruiz, M.E., Vanpouille-Box, C., Melero, I., Formenti, S.C. and Demaria, S. (2018) Immunological Mechanisms Responsible for Radiation-Induced Abscopal Effect. Trends in Immunology, 39, 644-655. [Google Scholar] [CrossRef] [PubMed]
[14] Demaria, S., et al. (2004) Ionizing Radiation Inhibition of Distant Un-treated Tumors (Abscopal Effect) Is Immune Mediated. International Journal of Radiation Oncology∙Biology∙Physics, 58, 862-870. [Google Scholar] [CrossRef] [PubMed]
[15] Citrin, D.E. (2017) Recent Developments in Radiotherapy. The New England Journal of Medicine, 377, 1065-1075. [Google Scholar] [CrossRef
[16] Procureur, A., et al. (2021) Enhance the Immune Checkpoint Inhibi-tors Efficacy with Radiotherapy Induced Immunogenic Cell Death: A Comprehensive Review and Latest Developments. Cancers, 13, Article 678. [Google Scholar] [CrossRef] [PubMed]
[17] Jarosz-Biej, M., et al. (2019) Tumor Microenvironment as a “Game Changer” in Cancer Radiotherapy. International Journal of Molecular Sciences, 20, Article 3212. [Google Scholar] [CrossRef] [PubMed]
[18] Wang, N., et al. (2022) Radiation-Induced PD-L1 Expression in Tumor and Its Microenvironment Facilitates Cancer-Immune Escape: A Narrative Review. Annals of Translational Medicine, 10, 1-15, [Google Scholar] [CrossRef] [PubMed]
[19] Gallo, P.M. and Gallucci, S. (2013) The Dendritic Cell Response to Classic, Emerging and Homeostatic Danger Signals. Implications for Autoimmunity. Frontiers in Immunology, 4, Article 138. [Google Scholar] [CrossRef] [PubMed]
[20] Merrick, A., et al. (2005) Immunosuppressive Effects of Radiation on Human Dendritic Cells: Reduced IL-12 Production on Activation and Impairment of Naive T-cell Priming. British Journal of Cancer, 92, 1450-1458. [Google Scholar] [CrossRef] [PubMed]
[21] Wunderlich, R., Ernst, A., Rödel, F., Fietkau, R., Ott, O., Lauber, K., Frey, B. and Gaipl, U.S. (2015) Low and Moderate Doses of Ionizing Radiation up to 2 Gy Modulate Transmigration and Chemotaxis of Activated Macrophages, Provoke an Anti-Inflammatory Cytokine Milieu, but Do Not Impact upon Viability and Phagocytic Function. Clinical and Experimental Immunology, 179, 50-61. [Google Scholar] [CrossRef] [PubMed]
[22] Matsumura, S., et al. (2008) Radiation-Induced CXCL16 Release by Breast Cancer Cells Attracts Effector T Cells. The Journal of Immunology, 181, 3099-3107. [Google Scholar] [CrossRef] [PubMed]
[23] Gupta, A., et al. (2012) Radiotherapy Promotes Tumor-Specific Effector CD8+ T Cells via Dendritic Cell Activation. The Journal of Immunology, 189, 558-566. [Google Scholar] [CrossRef] [PubMed]
[24] Thomas, D.A. and Massagué, J. (2005) TGF-β Directly Targets Cytotoxic T Cell Functions during Tumor Evasion of Immune Surveillance. Cancer Cell, 8, 369-380. [Google Scholar] [CrossRef] [PubMed]
[25] Lee, Y., et al. (2009) Therapeutic Effects of Ablative Radiation on Local Tumor Require CD8+ T Cells: Changing Strategies for Cancer Treatment. Blood, 114, 589-595. [Google Scholar] [CrossRef] [PubMed]
[26] Burnette, B.C., et al. (2011) The Efficacy of Radiotherapy Re-lies upon Induction of Type i Interferon-Dependent Innate and Adaptive Immunity. Cancer Research, 71, 2488-2496. [Google Scholar] [CrossRef
[27] Mouw, K.W., Goldberg, M.S., Konstantinopoulos, P.A. and D’Andrea, A.D. (2017) DNA Damage and Repair Biomarkers of Immunotherapy Response. Cancer Discovery, 7, 675-693. [Google Scholar] [CrossRef
[28] Cloosen, S., Arnold, J., Thio, M., Bos, G.M.J., Kyewski, B. and Germeraad, W.T.V. (2007) Expression of Tumor-Asso- ciated Differentiation Antigens, MUC1 Gly-coforms and CEA, in Human Thymic Epithelial Cells: Implications for Self-Tolerance and Tumor Therapy. Cancer Re-search, 67, 3919-3926. [Google Scholar] [CrossRef
[29] Wang, Y., Shi, T., Song, X., Liu, B. and Wei, J. (2021) Gene Fusion Neoantigens: Emerging Targets for Cancer Immunotherapy. Cancer Letters, 506, 45-54. [Google Scholar] [CrossRef] [PubMed]
[30] Aleksic, M., et al. (2012) Different Affinity Windows for Virus and Cancer-Specific T-Cell Receptors: Implications for Therapeutic Strategies. European Journal of Immunology, 42, 3174-3179. [Google Scholar] [CrossRef] [PubMed]
[31] Tan, M.P., et al. (2015) T Cell Receptor Binding Affinity Governs the Functional Profile of Cancer-Specific CD8+ T Cells. Clinical and Experimental Immunology, 180, 255-270. [Google Scholar] [CrossRef] [PubMed]
[32] Bhalla, N., Brooker, R. and Brada, M. (2018) Combining Immunotherapy and Radiotherapy in Lung Cancer. Journal of Thoracic Disease, 10, S1447-S1460. [Google Scholar] [CrossRef] [PubMed]
[33] Demaria, S. and Formenti, S.C. (2012) Role of T Lymphocytes in Tumor Response to Radiotherapy. Frontiers in Oncology, 2, Article 95. [Google Scholar] [CrossRef] [PubMed]
[34] Boone, B.A. and Lotze, M.T. (2014) Targeting Damage-Associated Molecular Pattern Molecules (DAMPs) and DAMP Receptors in Melanoma. In: Thurin, M. and Marincola, F., Eds., Molecular Diagnostics for Melanoma, Methods in Molecular Biology, Vol. 1102, Humana Press, Totowa, 537-552. [Google Scholar] [CrossRef] [PubMed]
[35] Vanpouille-Box, C., et al. (2017) DNA Exonuclease Trex1 Regulates Radiotherapy-Induced Tumour Immunogenicity. Nat Commun, 8, Article No. 15618. [Google Scholar] [CrossRef] [PubMed]
[36] Vanpouille-Box, C., Formenti,, S.C. and Demaria, S. (2017) TREX1 Dictates the Immune Fate of Irradiated Cancer Cells. Oncoimmunology, 6, e1339857. [Google Scholar] [CrossRef
[37] Lugade, A.A., et al. (2008) Radiation-Induced IFN-Gamma Production within the Tumor Microenvironment Influences Antitumor Immunity. The Journal of Immunology, 180, 3132-3139. [Google Scholar] [CrossRef] [PubMed]
[38] Tabi, Z., et al. (2010) Resistance of CD45RA-T Cells to Apoptosis and Functional Impairment and Activation of Tumor-Antigen Specific T Cells during Radiation Ther-apy of Prostate Cancer. The Journal of Immunology, 185, 1330- 1339. [Google Scholar] [CrossRef] [PubMed]
[39] Ma, Y., Pitt, J.M., Li, Q. and Yang, H. (2017) The Renaissance of Anti-Neoplastic Immunity from Tumor Cell Demise. Immunological Reviews, 280, 194-206. [Google Scholar] [CrossRef] [PubMed]
[40] Sundahl, N., et al. (2019) Randomized Phase 1 Trial of Pembrolizumab with Sequential Versus Concomitant Stereotactic Body Radiotherapy in Metastatic Urothelial Carcinoma. European Urology, 75, 707-711. [Google Scholar] [CrossRef] [PubMed]
[41] Qin, R., et al. (2016) Safety and Efficacy of Radiation Therapy in Advanced Melanoma Patients Treated with Ipilimumab. International Journal of Radiation Oncology, Biology, Physics, 96, 72-77. [Google Scholar] [CrossRef] [PubMed]
[42] Dovedi, S.J., et al. (2014) Acquired Resistance to Fractionated Radiotherapy Can Be Overcome by Concurrent PD-L1 Blockade. Cancer Research, 74, 5458-5468. [Google Scholar] [CrossRef
[43] Reynders, K., et al. (2015) The Abscopal Effect of Local Radiotherapy: Using Immunotherapy to Make a Rare Event Clinically Relevant. Cancer Treatment Reviews, 41, 503-510. [Google Scholar] [CrossRef] [PubMed]
[44] Pinedo, H.M., et al. (2003) Extended Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer Combined with GM-CSF: Effect on Tumour-Draining Lymph Node Dendritic Cells. European Journal of Cancer, 39, 1061-1067. [Google Scholar] [CrossRef
[45] Siva, S., MacManus, M.P., Martin, R.F. and Martin, O.A. (2015) Abscopal Effects of Radiation Therapy: A Clinical Review for the Radiobiologist. Cancer Letters, 356, 82-90. [Google Scholar] [CrossRef] [PubMed]
[46] Dewan, M.Z., et al. (2009) Fractionated but Not Single-Dose Ra-diotherapy Induces an Immune-Mediated Abscopal Effect when Combined with Anti-CTLA-4 Antibody. Clinical Can-cer Research, 15, 5379-5388. [Google Scholar] [CrossRef
[47] Wang, K., et al. (2023) Intensity-Modulated Radiotherapy Combined with Systemic Atezolizumab and Bevacizumab in Treatment of Hepatocellular Carcinoma with Extrahepatic Portal Vein Tumor Thrombus: A Preliminary Multicenter Single-Arm Prospective Study. Frontiers in Immunology, 14, Article 1107542. [Google Scholar] [CrossRef] [PubMed]
[48] Wang, W., Huang, C., Wu, S., Liu, Z., Liu, L. Li, L. and Li, S. (2020) Abscopal Effect Induced by Modulated Radiation Therapy and Pembrolizumab in a Patient with Pancreatic Meta-static Lung Squamous Cell Carcinoma. Thoracic Cancer, 11, 2014-2017. [Google Scholar] [CrossRef] [PubMed]
[49] Belgioia, L., et al. (2019) Safety and Efficacy of Combined Radio-therapy, Immunotherapy and Targeted Agents in Elderly Patients: A Literature Review. Critical Reviews in Oncolo-gy/Hematolog, 133, 163-170. [Google Scholar] [CrossRef] [PubMed]
[50] Kroeze, S.G., et al. (2017) Toxicity of Concurrent Stereotactic Radiotherapy and Targeted Therapy or Immunotherapy: A Systematic Review. Cancer Treatment Reviews, 53, 25-37. [Google Scholar] [CrossRef] [PubMed]
[51] Grimaldi, A.M., et al. (2014) Abscopal Effects of Radiotherapy on Advanced Melanoma Patients Who Progressed after Ipilimumab Immunotherapy. Oncoimmunology, 3, e28780. [Google Scholar] [CrossRef] [PubMed]
[52] Woo, S.R., et al. (2012) Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-Cell Function to Promote Tumoral Immune Escape. Cancer Research, 72, 917-927. [Google Scholar] [CrossRef
[53] Ruffo, E., Wu, R.C., Bruno, T.C., Workman, C.J. and Vignali, D.A.A. (2019) Lymphocyte-Activation Gene 3 (LAG3): The Next Immune Checkpoint Receptor. Seminars in Immunology, 42, Article ID: 101305. [Google Scholar] [CrossRef] [PubMed]
[54] Strigari, L., et al. (2014) Abscopal Effect of Radiation Therapy: Interplay between Radiation Dose and p53 Status. International Journal of Radiation Biology, 90, 248-255. [Google Scholar] [CrossRef] [PubMed]
[55] Camphausen, K., et al. (2003) Radiation Abscopal Antitumor Effect Is Mediated through p53. Cancer Research, 63, 1990-1993.